Facilitated By

San Antonio Medical Foundation

A Phase 3, Open Label, Randomized Study Of LOXO-305 Versus Investigator’s Choice Of Idelalisib Plus Rituximab Or Bendamustine Plus Rituximab In Btk Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Brooke Army Medical Center

Brooke Army Medical Center (BAMC) at Fort Sam Houston, Texas, is proud to provide safe, quality care to our military service members, their families, veterans and civilian emergency patients as the most robust and productive healthcare organization within the Military Health System (MHS).

Principal Investigator(s)
Email for information
Funded by
Research Start Date

The primary objective of the study is to evaluate progression-free survival of LOXO-305 as monotherapy (Arm A) versus either idelalisib plus rituximab or bendamustine plus rituximab (Arm B).

Collaborative Project
Clinical Care
The appearance of name-brand products in this article does not constitute endorsement by Brooke Army Medical Center, the U.S. Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, the Department of Defense, or the U.S. Government of the information, products, or services contained therein.